Clinical Trial

Application of Endoscopic Selective Neck Dissection Under Multimodal Assessment for Residual Cervical Lymph Nodes in N3 Nasopharyngeal Carcinoma After Radiotherapy

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this phase I clinical trial is to learn whether a multimodal follow-up evaluation combined with endoscopic selective neck dissection (ESND) is safe and feasible in patients with newly diagnosed N3 nasopharyngeal carcinoma. The main questions it aims to answer are: * Is the multimodal evaluation-guided surveillance-intervention approach safe for patients? * Is this approach feasible for identifying and managing residual cervical lymph nodes after radiotherapy? Participants will receive standard chemoradiotherapy. After treatment, they will undergo follow-up evaluation using clinical assessment, conventional imaging, Epstein-Barr virus DNA testing, and contrast-enhanced ultrasound. Participants with clinically suspicious residual cervical lymph nodes identified by multimodal evaluation and eligible for surgery underwent endoscopic selective neck dissection.
Trial Details
NCT Number NCT07636499
Lead Sponsor Guiquan Zhu
Conditions Nasopharyngeal Cancinoma (NPC)
Enrollment 50 participants
Start Date 2022-08-30
Primary Completion 2025-08-30 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-09